Amphastar Pharma (AMPH) Misses Q4 EPS by 20c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.20 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $183.1 million versus the consensus estimate of $191.76 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Alpha Compute reports $1.57M monthly cash flow and $1.5B pipeline
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral